| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alzamend Neuro Inc. | AL001-BD01 | Bipolar Disorder | Phase 2a | Trial Planned | Oral | Psychiatric |
| Alzamend Neuro Inc. | AL001 | Healthy human subjects | Phase 2 | Ongoing | oral | N/A |
| Alzamend Neuro Inc. | AL001 | Post-traumatic stress disorder (PTSD) | Phase 2 | Trial Planned | oral | Psychiatric |
| Alzamend Neuro Inc. | AL001 | Dementia related to Alzheimer's | Phase 2a | Study May Proceed Letter | oral | Neurology |
| Alzamend Neuro Inc. | AL001 | Alzheimer's disease (AD) | Phase 2 | Trial Planned | oral | Neurology |
| Alzamend Neuro Inc. | AL001 | Dementia related to Alzheimer's | Phase 2a | Study May Proceed Letter | oral | Neurology |
| Amarin Corporation plc | VASCEPA (Icosapent Ethyl)- (PREPARE-IT) | Covid-19 | Phase 3 | Data Released | Oral | COVID-19 |
| Amarin Corporation plc | VASCEPA (Icosapent Ethyl)- (PREPARE-IT) | Covid-19 | Phase 3 | Data Released | Oral | COVID-19 |